Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5251MR)

This product GTTS-WQ5251MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5251MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15366MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ10822MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ6742MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ14066MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ1438MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ10975MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ8779MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ536MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW